Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study
Daniel Q. Huang(National University of Singapore), Rohit Loomba(University of California San Diego), Scarlett Lopez(University of California San Diego), Harris Siddiqi(University of California San Diego), Hannele Yki‐Järvinen(University of Helsinki), Katriina Nemes(University of Helsinki), Panu K. Luukkonen(University of Helsinki), Richele Bettencourt(University of California San Diego), Christie Hernandez(University of California San Diego), Helena Isoniemi(University of Helsinki), Kimmo Porthan(Helsinki University Hospital), Vanessa Cervantes(University of California San Diego), Maral Amangurbanova(University of California San Diego), Egbert Madamba(University of California San Diego), Lisa Richards(University of California San Diego), Noora Ahlholm(University of Helsinki)
Cited by 13
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k